Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gombash, Sara E ^a,b   Manfredsson, Fredric P ^b   Kemp, Christopher J ^b   Kuhn, Nathan C ^b   Fleming, Sheila M ^a   Egan, Ann E ^a   Grant, Laura M ^c   Ciucci, Michelle R ^c   MacKeigan, Jeffrey P ^d   Sortwell, Caryl E ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GREEN FLUORESCENT PROTEIN; TYROSINE 3 MONOOXYGENASE; SNCA PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COHORT ANALYSIS; EXPRESSION VECTOR; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SEROTYPE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; CELL DEATH; CYTOLOGY; DEPENDOPARVOVIRUS; FORELIMB; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; VOCALIZATION;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; CELL DEATH; DEPENDOVIRUS; FORELIMB; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VOCALIZATION, ANIMAL;

EID: 84896694412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081426     Document Type: Article

References (57)

1. Polymeropoulos MH (1998) Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 44: S63-S64. PubMed: 9749575.
2. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841. doi:10.1126/science.1090278. PubMed: 14593171.
3. Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F et al. (2009) Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 66: 102-108. doi:10.1001/archneurol.2008.555. PubMed: 19139307.
4. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473. doi:10.1073/pnas.95.11.6469. PubMed: 9600990.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840. doi:10.1038/42166. PubMed: 9278044.
6. Yavich L, Tanila H, Vepsäläinen S, Jäkälä P (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 24: 11165-11170. doi:10.1523/JNEUROSCI.2559-04.2004. PubMed: 15590933.
7. Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C et al. (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133: 2032-2044. doi:10.1093/brain/ awq132. PubMed: 20534649.
8. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79. doi:10.1016/j.neuron.2009.12.023. PubMed: 20152114.
9. Lundblad M, Decressac M, Mattsson B, Björklund A (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 109: 3213-3219. doi:10.1073/pnas.1200575109. PubMed: 22315428.
10. Lee HJ, Kang SJ, Lee K, Im H (2011) Human alpha-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. Biochem Biophys Res Commun 412: 526-531. doi:10.1016/j.bbrc.2011.07.028. PubMed: 21798244.
11. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 286: 20710-20726. doi:10.1074/jbc.M110.213538. PubMed: 21489994.
12. Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M et al. (2008) Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci 28: 12305-12317. doi:10.1523/ JNEUROSCI.3088-08.2008. PubMed: 19020024.
13. Devi L, Anandatheerthavarada HK (2010) Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 1802: 11-19. doi:10.1016/j.bbadis. 2009.07.007. PubMed: 19619643.
14. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F et al. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. Journal of Neuroscience : the Official Journal of the Society for Neuroscience 22: 3090-3099.
15. Wersinger C, Sidhu A (2005) Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44: 13612-13624. doi:10.1021/bi050402p. PubMed: 16216085.
16. Wersinger C, Sidhu A (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340: 189-192. doi:10.1016/S0304-3940(03)00097- 1. PubMed: 12672538.
17. Yu S, Zuo X, Li Y, Zhang C, Zhou M et al. (2004) Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367: 34-39. doi:10.1016/j.neulet.2004.05.118. PubMed: 15308292.
18. Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG (2006) Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem 99: 1188-1196. doi:10.1111/j.1471-4159.2006. 04146.x. PubMed: 16981894.
19. Kanaan NM, Manfredsson FP (2012) Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? Journal Parkinson'S Disease 2: 249-267. PubMed: 23938255.
20. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791. PubMed: 11923443.
21. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P (2002) alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 99: 10813-10818. doi:10.1073/pnas.152339799. PubMed: 12122208.
22. Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B et al. (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 13: 364-372. PubMed: 12946025.
23. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91: 451-461. doi:10.1111/j.1471-4159.2004.02728.x. PubMed: 15447678.
24. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLOS ONE 5: e8784. doi:10.1371/journal.pone.0008784. PubMed: 20098715.
25. Ulusoy A, Decressac M, Kirik D, Björklund A (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res 184: 89-111. doi:10.1016/S0079-6123(10) 84005-1. PubMed: 20887871.
26. Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45: 939-953. doi:10.1016/j.nbd.2011.12.013. PubMed: 22182688.
27. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G et al. (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105: 763-768. doi:10.1073/pnas.0711053105. PubMed: 18178617.
28. Yamada M, Mizuno Y, Mochizuki H (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 16: 262-270. doi:10.1089/hum.2005.16.262. PubMed: 15761265.
29. Decressac M, Mattsson B, Björklund A (2012) Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 235: 306-315. doi:10.1016/j. expneurol.2012.02.012. PubMed: 22394547.
30. Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M et al. (2011) GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain : a Journal of Neurology 134: 2302-2311. doi:10.1093/brain/awr149.
31. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67: 715-725. doi:10.1002/ana.21995. PubMed: 20517933.
32. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 32: 409-422. doi:10.1111/j.1460-9568.2010.07284.x. PubMed: 20704592.
33. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P et al. (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317. doi:10.1016/j.ymthe.2004.05.024. PubMed: 15294177.
34. Gombash SE, Lipton JW, Collier TJ, Madhavan L, Steece-Collier K et al. (2012) Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Mol Ther 20: 544-554. doi:10.1038/mt.2011.216. PubMed: 22008908.
35. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985. doi:10.1038/sj.gt.3300938. PubMed: 10455399.
36. Schallert T (2006) Behavioral tests for preclinical intervention assessment. NeuroRx 3: 497-504. doi:10.1016/j.nurx.2006.08.001. PubMed: 17012064.
37. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39: 777-787. doi:10.1016/S0028-3908(00)00005-8. PubMed: 10699444.
38. Schallert T, Upchurch M, Lobaugh N, Farrar SB, Spirduso WW et al. (1982) Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol Biochem Behav 16: 455-462. doi:10.1016/0091-3057(82)90452-X. PubMed: 7079281.
39. Schallert T, Upchurch M, Wilcox RE, Vaughn DM (1983) Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum. Pharmacol Biochem Behav 18: 753-759. doi:10.1016/0091-3057(83)90019-9. PubMed: 6407036.
40. Olsson M, Nikkhah G, Bentlage C, Björklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15: 3863-3875. PubMed: 7751951.
41. Schallert T, De Ryck M, Whishaw IQ, Ramirez VD, Teitelbaum P (1979) Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp Neurol 64: 33-43. doi:10.1016/0014-4886(79) 90003-7. PubMed: 428497.
42. Basken JN, Connor NP, Ciucci MR (2012) Effect of aging on ultrasonic vocalizations and laryngeal sensorimotor neurons in rats. Exp Brain Res 219: 351-361. doi:10.1007/s00221-012-3096-6. PubMed: 22562586.
43. Bialy M, Rydz M, Kaczmarek L (2000) Precontact 50-kHz vocalizations in male rats during acquisition of sexual experience. Behav Neurosci 114: 983-990. doi:10.1037/0735-7044.114.5.983. PubMed: 11085613.
44. Ciucci MR, Ma ST, Fox C, Kane JR, Ramig LO et al. (2007) Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav Brain Res 182: 284-289. doi:10.1016/j.bbr.2007.02.020. PubMed: 17397940.
45. Ringel LE, Basken JN, Grant LM, Ciucci MR (2013) Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations. Behav Brain Res 252: 252-259. doi:10.1016/j.bbr.2013.06.006. PubMed: 23764460.
46. Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D et al. (2012) Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-alpha-synuclein and the pesticide, rotenone. Neuroscience 203: 170-179. doi:10.1016/j.neuroscience.2011. 12.011. PubMed: 22198020.
47. Nikolaus S, Larisch R, Beu M, Forutan F, Vosberg H et al. (2003) Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 30: 390-395. doi:10.1007/s00259-002-1056-2. PubMed: 12634967.
48. Day M, Wang Z, Ding J, An X, Ingham CA et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259. doi:10.1038/nn1632. PubMed: 16415865.
49. Ciucci MR, Ahrens AM, Ma ST, Kane JR, Windham EB et al. (2009) Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats. Behav Neurosci 123: 328-336. doi:10.1037/a0014593. PubMed: 19331456.
50. Brudzynski SM (2005) Principles of rat communication: quantitative parameters of ultrasonic calls in rats. Behav Genet 35: 85-92. doi:10.1007/s10519-004-0858-3. PubMed: 15674535.
51. Brudzynski SM, Ociepa D (1992) Ultrasonic vocalization of laboratory rats in response to handling and touch. Physiol Behav 52: 655-660. doi:10.1016/0031-9384(92)90393-G. PubMed: 1409936.
52. Brudzynski SM, Pniak A (2002) Social contacts and production of 50-kHz short ultrasonic calls in adult rats. J Comp Psychol 116: 73-82. doi:10.1037/0735-7036.116.1.73. PubMed: 11926686.
53. McGinnis MY, Vakulenko M (2003) Characterization of 50-kHz ultrasonic vocalizations in male and female rats. Physiol Behav 80: 81-88. doi:10.1016/S0031-9384(03)00227-0. PubMed: 14568311.
54. Johnson AM, Ciucci MR, Russell JA, Hammer MJ, Connor NP (2010) Ultrasonic output from the excised rat larynx. J Acoust Soc Am 128: EL75-79.
55. Riede T (2011) Subglottal pressure, tracheal airflow, and intrinsic laryngeal muscle activity during rat ultrasound vocalization. J Neurophysiol 106: 2580-2592. doi:10.1152/jn.00478.2011. PubMed: 21832032.
56. Darley FL, Aronson AE, Brown JR (1969) Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 12: 462-496. PubMed: 5811846.
57. Plowman-Prine EK, Okun MS, Sapienza CM, Shrivastav R, Fernandez HH et al. (2009) Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. Neurorehabilitation 24: 131-144. PubMed: 19339752.